Compare FINV & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | EVO |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | FINV | EVO |
|---|---|---|
| Price | $4.96 | $3.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.55 | $7.00 |
| AVG Volume (30 Days) | ★ 1.0M | 250.0K |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $1,969,555,571.00 | $887,396,457.00 |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | N/A | $8.52 |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $4.70 | $2.84 |
| 52 Week High | $11.08 | $4.80 |
| Indicator | FINV | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 66.92 |
| Support Level | $5.17 | $3.10 |
| Resistance Level | $5.49 | $3.69 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 3.03 | 89.02 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.